2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 52

Pregabalin Dose-Response for Sleep Quality and Pain Response in Fibromyalgia: A Post-Hoc Analysis of Three Randomized Trials
Abstract Number: 3131

Pregabalin Is More Effective in Treating Hand Osteoarthritis Pain Than Duloxetine or Placebo: A Double-Blind Randomized Controlled Trial
Abstract Number: 2443

Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study
Abstract Number: 2553

Pregnancy Outcomes in Patients with Rheumatoid Arthritis Treated with Abatacept – Review of a Safety Database
Abstract Number: 1533

Pregnancy Outcomes in Women with Rheumatoid Arthritis : A Systematic Review and Meta-Analyses
Abstract Number: 2902

Preliminary Evaluation of Gastroesophageal Reflex Disease Outcome Measures in Scleroderma– Scleroderma Clinical Trials Consortium Gastrointestinal Working Group
Abstract Number: 3208

Preliminary Response to JAK1/2 Inhibition with Baricitinib in “Candle”,“Savi” and “Candle-like” Diseases. a New Therapeutic Approach for Type I IFN Mediated Autoinflammatory Diseases
Abstract Number: 893

Preliminary Results of a Multi Modal Imaging Study Suggests a Better Accuracy for the Diagnosis of Giant Cell Arteritis
Abstract Number: 2317

Preliminary Validation of a Magnetic Resonance Imaging-Based Inflammatory Scoring System in Adult Myositis
Abstract Number: 1400

Preliminary Validation of the Turkish Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY) in a Single Center
Abstract Number: 2052

Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort
Abstract Number: 1228

Prescribing for Children with Rheumatologic Disease: Differences Between Pediatric and Adult Rheumatologists
Abstract Number: 2169

Presence of Cardiovascular Risk Factors Across Different Inflammatory Joint Disease Entities: Results from a Norwegian, Multi-Centre Project
Abstract Number: 219

Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol
Abstract Number: 342

Presence of Vertebral Fractures and Disc Disease in Post Menopausal Females with Height Loss As a Possible Screening Method for Osteoporosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].